Collins Stewart initiates coverage on Genzyme (Nasdaq: GENZ) with a Buy rating and $79 price target, citing multiple near-term catalysts ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE